About: Dimercaprol     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
http://linked.open...gbank/description
  • Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II. It was developed as an experimental antidote against the arsenic-based poison gas Lewisite. It has been used clinically since 1949 in arsenic, cadmium and mercury poisoning. In addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper. Dimercaprol is a potentially toxic drug, and its use may be accompanied by multiple side effects. (en)
http://linked.open...y/drugbank/dosage
http://linked.open...generalReferences
  • # Walshe JM: The conquest of Wilson's disease. Brain. 2009 Aug;132(Pt 8):2289-95. Epub 2009 Jul 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19596747 # Boscolo M, Antonucci S, Volpe AR, Carmignani M, Di Gioacchino M: Acute mercury intoxication and use of chelating agents. J Biol Regul Homeost Agents. 2009 Oct-Dec;23(4):217-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20003760 # Flora SJ, Pachauri V: Chelation in metal intoxication. Int J Environ Res Public Health. 2010 Jul;7(7):2745-88. Epub 2010 Jun 28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20717537 # Andersen O: Chemical and biological considerations in the treatment of metal intoxications by chelating agents. Mini Rev Med Chem. 2004 Jan;4(1):11-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14754439 (en)
http://linked.open...gy/drugbank/group
  • approved (en)
http://linked.open...drugbank/halfLife
  • The drug has a short half life. (en)
http://linked.open...ugbank/indication
  • For the treatment of arsenic, gold and mercury poisoning. Indicated in acute lead poisoning when used concomitantly with edetate calcium disodium (DB00974). (en)
sameAs
Title
  • Dimercaprol (en)
adms:identifier
http://linked.open...mechanismOfAction
  • The sulfhydryl groups of dimercaprol form complexes with certain heavy metals thus preventing or reversing the metallic binding of sulfhydryl-containing enzymes. The complex is excreted in the urine. (en)
http://linked.open...outeOfElimination
  • Urine. (en)
http://linked.open.../drugbank/synonym
  • 2,3-Dimercapro (en)
  • 2,3-Dimercaptopropanol (en)
  • BAL (en)
  • British Anti-Lewisite (en)
  • 1,2-Dimercapto-3-propanol (en)
  • 1,2-Dithioglycerol (en)
  • 2,3-Dimercapto-1-propanol (en)
  • 2,3-Dimercaptol-1-propanol (en)
  • 2,3-Dithiopropanol (en)
  • 2,3-Mercaptopropan-1-ol (en)
  • 2,3-Mercaptopropanol (en)
  • 3-Hydroxy-1,2-propanedithiol (en)
  • British antilewisite (en)
  • Dimercaprolum (en)
  • Dimercaptopropanol (en)
  • Dithioglycerine (en)
  • Dithioglycerol (en)
  • Sulfactin (en)
  • alpha,beta-Dithioglycerol (en)
http://linked.open...drugbank/toxicity
  • The intramuscular LD50 in rats is approximately 105 mg/kg; intraperitoneally 140 mg/kg. The intraperitoneal LD80 in mice is approximately 125 mg/kg. Dimercaprol has been shown in animal experiments to increase brain deposition of arsenite, organic mercury compounds and increase the toxicity of cadmium and lead. Dimercaprol has been shown to induce seizure in animal studies and also is nephrotoxic. (en)
http://linked.open.../drug/hasAHFSCode
http://linked.open.../drugbank/mixture
http://linked.open...ynthesisReference
  • Peppel, W.J. and Signaigo, F.K.; U.S. Patent 2,402,665; June 25,1946; assigned to E.I. du Pont de Nemwrs & Company. (en)
http://linked.open...ugbank/IUPAC-Name
http://linked.open...gy/drugbank/InChI
http://linked.open...Molecular-Formula
http://linked.open.../Molecular-Weight
http://linked.open...noisotopic-Weight
http://linked.open...y/drugbank/SMILES
http://linked.open.../Water-Solubility
http://linked.open...ogy/drugbank/logP
http://linked.open...ogy/drugbank/logS
http://linked.open...logy/drugbank/pKa
http://linked.open...l/drug/hasATCCode
http://linked.open...nd-Acceptor-Count
http://linked.open...-Bond-Donor-Count
http://linked.open...drugbank/InChIKey
http://linked.open...urface-Area--PSA-
http://linked.open...nk/Polarizability
http://linked.open...bank/Refractivity
http://linked.open...atable-Bond-Count
http://linked.open...ugbank/absorption
  • After intra-muscular injection. (en)
http://linked.open...casRegistryNumber
  • 59-52-9 (en)
http://linked.open...drugbank/category
  • (en)
http://linked.open...k/Bioavailability
http://linked.open...ank/Boiling-Point
http://linked.open...bank/Ghose-Filter
http://linked.open...nk/MDDR-Like-Rule
http://linked.open...ank/Melting-Point
http://linked.open...k/Number-of-Rings
http://linked.open...siological-Charge
http://linked.open...bank/Rule-of-Five
http://linked.open...tional-IUPAC-Name
http://linked.open...strongest-acidic-
http://linked.open...-strongest-basic-
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 47 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software